LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Werfen Introduces GEM Premier 7000 with iQM3 Blood Gas Testing System

By LabMedica International staff writers
Posted on 30 Jul 2024
Image: The GEM Premier 7000 with Intelligent Quality Management 3 (iQM3) is being unveiled at ADLM 2024 (Photo courtesy of Werfen)
Image: The GEM Premier 7000 with Intelligent Quality Management 3 (iQM3) is being unveiled at ADLM 2024 (Photo courtesy of Werfen)

At the ADLM 2024 Clinical Lab Expo, Werfen (Barcelona, Spain) is featuring its range of hemostasis, acute care, autoimmunity, transfusion and transplant systems, reagents, and digital solutions, and also unveiling its newest innovation in point-of-care (POC) detection.

As the number one source of preanalytical error, hemolysis accounts for up to 70% of all such errors. Despite its prevalence throughout the hospital, hemolysis is not visible in whole blood, and can often go unrecognized. The consequences of in vitro hemolysis can include inappropriate patient management, increased length of stay, and increased costs, among others. At this year’s ADLM Annual Meeting, Werfen is introducing the GEM Premier 7000 with Intelligent Quality Management 3 (iQM3), a breakthrough in blood gas testing that detects hemolysis at the POC.

The GEM Premier 7000 with iQM3 is a portable critical care system for use by health care professionals to rapidly analyze lithium heparinized whole blood samples at the point of health care delivery in a clinical setting and a central laboratory. The instrument provides quantitative measurements of pH, pCO2, pO2, sodium, potassium, chloride, ionized calcium, glucose, lactate, hematocrit, total bilirubin, and CO-Oximetry (tHb, O2Hb, COHb, MetHb, HHb, sO2) parameters from arterial, venous, or capillary lithium heparinized whole blood. These parameters, along with derived parameters, aid in the diagnosis of a patient’s acid/base status, electrolyte and metabolite balance and oxygen delivery capacity.

Werfen is providing a virtual reality laboratory experience to visitors at its booth where they can see 3D customized layouts of HemoCell specialized lab automation workcells for hemostasis labs of all sizes, shapes, and volumes. They can also see how Werfen’s comprehensive autoimmune diagnostics solution can help advance a lab’s capabilities by optimizing efficiency and enhancing clinical decision-making. Additionally, Werfen is presenting an industry workshop titled, Challenges in Pre-Analytical Error Detection: Impact of Hemolysis and Potential Solutions. The workshop will focus on the challenges in pre-analytical error detection, including hemolysis, its prevalence, and its impact on potassium and clinical outcomes. Current strategies and the company’s new technology to detect hemolysis for mitigating risks at the POC will also be discussed.

Related Links:
Werfen

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
8-Channel Pipette
SAPPHIRE 20–300 µL

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more